We Need to Preserve Equitable Access to Critical Medication . Pass the Kidney PATIENT Act Now!
Americans on dialysis need help from Congress to ensure they have access to much needed innovative treatments.
Nearly 70 stakeholders from patient advocacy groups, racial equity organizations, labor unions, and faith leaders wrote to Congress urging passage of the Kidney PATIENT Act (H.R. 5074) this year.
Americans who suffer from kidney failure, also called End Stage Renal Disease (ESRD), rely on medicines known as Phosphate Lowering Therapies (PLTs) to reduce their risk of death.
Disproportionate Impact on Minoritized Communities
– ESRD is one of the starkest examples of racial and/or ethnic disparities in health. Chronic kidney disease (CKD) is one of the fastest-growing chronic health conditions among minoritized communities and is associated with substantially increased risks of kidney failure.
– Black Americans suffer from the highest rates of ESRD and ESRD rates are nearly 35% higher among Hispanics compared with non-Hispanics.
(Source: National Library of Medicine)
– Black people make up just 13% of the U.S. population but account for 35% of Americans with kidney failure; they are nearly four times more likely than white people to develop it. (Source: National Kidney Foundation)
Unless Congress passes the Kidney PATIENT Act of 2023 (H.R. 5074), patients will face new restrictions to much-needed PLTs because their coverage will be moved into End Stage Renal Disease Prospective Payment System or “ESRD bundle” starting in 2025 which could result in serious consequences including:
The Kidney PATIENT Act of 2023 would delay CMS from adding PLTs to the ESRD bundle until January 1, 2033, or until an intravenous (IV) treatment for lowering phosphate has been approved by the Food and Drug Administration (FDA).
With your help, we can preserve access to quality care for patients on dialysis.